Vernon Bernardino: Hi, thanks for taking my question and congrats on the impressive growth. Just wanted to follow-up on the inventory question, but before that I couldn’t readily find the numbers right away, but could you remind us what the sales were for U.S. and ex-U.S. were in third quarter? And along those lines then with the inventory buildup, does Ascensia separate as far as inventory accounting, for example, ex-U.S. and U.S. or is it all one accounting? Just trying to figure out, let’s say, day sales and all that change in rate.
Tim Goodnow: Sure. Rick, do you want to take that?
Rick Sullivan: Sure, yes. Vernon, first part of your question, I think, was breakdown, U.S. and OUS. Maybe it was for fourth quarter, and so $8 million was the total. It was about $6 million in the U.S. and $2 million OUS for the quarter. And Ascensia does break out their inventory between the two geographies.
Vernon Bernardino: Okay. Do you anticipate, you said the inventory will be wound down in the next four months, which I guess is the rest of first half, do you anticipate any further build up before, let’s say, the launch of 365?
Rick Sullivan: I think we expect that by the end of the second quarter that Ascensia will get back to which our target of 60 to 90 days throughout the entire channel. And then after that we’ll provide guidance in the second quarter with how we think that transition from the six-month to 365-day product will go.
Vernon Bernardino: Great. Thanks for taking my question and my follow up.
Rick Sullivan: Sure.
Operator: The next question comes from Jayson Bedford with Raymond James. Please go ahead.
Unidentified Analyst: Hey, this is Glenn on for Jayson. And to start off, I just wanted to ask if you think the iCGM designation impacts commercial adoption or is it more of a vehicle to integrate with pumps?
Tim Goodnow: Well, it certainly is a vehicle to integrate with pumps. Obviously, especially in the Type 1 space, there are clinicians that see the iCGM as a validation of the system as a whole. So there can be MDI patients that the docs would like to put on the pump in the future, so iCGM is certainly influenced there. But it’s also, of course, an avenue to get into the million or so patients that currently are linked together and doing sensor augmented pumping.
Unidentified Analyst: Okay, thank you. And just to be clear, the 2Q revenue for just, for example, 2Q to Senseonics translate to implants in 3Q, I’m understanding that correctly?
Rick Sullivan: Approximately, yes. We see the target of 60 to 90 days from when we recognize revenue for it to go through the channel.
Unidentified Analyst: Okay, so how much of the $22 million and $23 million came from new patient sales? How much of that is in a patient now?
Rick Sullivan: I mean we’re not providing that level of detail since we recognize our revenue in advance of the insertion into the patient. And so there’s the time dynamic, and then there’s also the inventory dynamic, which we spoke to being a little bit ahead of our target inventory levels.
Unidentified Analyst: Okay, that was all. Thank you.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Tim Goodnow for any closing remarks.
Tim Goodnow: Great. Well, thank you all for joining. Once again we appreciate it, and we look forward to further updates here in a couple of months with our Q1 call. Thank you. Have a good day.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
